Critical Contrast: Sigyn Therapeutics (OTCMKTS:SIGY) versus CV Sciences (OTCMKTS:CVSI)

Insider & Institutional Ownership

10.0% of Sigyn Therapeutics shares are owned by institutional investors. 6.7% of CV Sciences shares are owned by company insiders. Comparatively, 78.5% of Sigyn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares CV Sciences and Sigyn Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CV Sciences	$13.79 million	0.34	-$960,000.00	N/A	N/A
Sigyn Therapeutics	N/A	N/A	-$3.34 million	($2.10)	-0.01

CV Sciences has higher revenue and earnings than Sigyn Therapeutics.

Profitability

This table compares CV Sciences and Sigyn Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CV Sciences	-11.15%	-94.61%	-20.85%
Sigyn Therapeutics	N/A	N/A	N/A

Risk & Volatility

CV Sciences has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Sigyn Therapeutics has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500.

Summary

Sigyn Therapeutics beats CV Sciences on 5 of the 8 factors compared between the two stocks.

About CV Sciences

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.